Neutrophils in Tumorigenesis and Progression: Dual Roles and Clinical Translation
Journal of Leukocyte Biology · 16.06.2026
DOI: 10.1093/jleuko/qiag079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 16.06.2026. Verfasst von Kexin Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, P.R. China. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Neutrophils, the most abundant innate immune cells, act as first responders in host defense via phagocytosis, degranulation, ROS production and Neutrophil Extracellular Traps (NETs) formation. Emerging evidence reveals that neutrophils are highly plastic and heterogeneous, acting as critical regulators in tumor biology. Tumor-derived CXCL8 and G-CSF drive emergency granulopoiesis, neutrophil recruitment and functional reprogramming, leading to immune suppression, angiogenesis, matrix remodeling, metastasis and therapy resistance. In specific contexts, neutrophils also exert anti-tumor effects by direct cytotoxicity, enhancing T-cell responses and restricting metastasis, displaying a dual role in cancer. Notably, anti-tumor neutrophils are rare in steady-state tumors but emerge during therapy-induced immune remodeling. Single-cell and spatial multi-omics have challenged the classical N1/N2 dichotomy. Tumor-associated neutrophils (TANs) and polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are now viewed as overlapping, dynamic populations along a functional continuum, shaped by maturation, metabolism, hypoxia and tissue niches. This review summarizes the dual roles of neutrophils in tumor progression, abnormal granulopoiesis, functional polarization, and revised concepts of TANs and PMN-MDSCs. We highlight NETosis, immune suppression, metabolic reprogramming and therapy resistance, and outline clinical translation including biomarkers (e.g., NLR) and therapeutic strategies. Current challenges and future directions are discussed, aiming to precisely target pro-tumor neutrophils while preserving host antimicrobial immunity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, P.R. China.
- College of Pharmacy, Xinjiang Medical University, Urumqi, 830054, P.R. China.
- School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming, 650580, P.R. China.
- State Key Laboratory of Natural Medicines, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, P.R. China.
- General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, P.R. China.
- School of Basic Medicine & Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, P.R. China.
ORCID-Profile: Hongyu Li, Qianming Du
Zitieren
APA
Hu, K., Li, H., Huang, P., Zhang, X., Hu, R., & Du, Q. (2026). Neutrophils in Tumorigenesis and Progression: Dual Roles and Clinical Translation. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiag079
Vancouver
Hu K, Li H, Huang P, Zhang X, Hu R, Du Q. Neutrophils in Tumorigenesis and Progression: Dual Roles and Clinical Translation. Journal of Leukocyte Biology. 2026. doi:10.1093/jleuko/qiag079
BibTeX
@article{Hu2026,
author = {Hu, Kexin and Li, Hongyu and Huang, Puwei and Zhang, Xiyue and Hu, Rong and Du, Qianming},
title = {Neutrophils in Tumorigenesis and Progression: Dual Roles and Clinical Translation},
journal = {Journal of Leukocyte Biology},
year = {2026},
doi = {10.1093/jleuko/qiag079}
}
EUVIMED